Clinical trials: Osimertinib

Non-Small Cell Lung Cancer (NSCLC)

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

• Active, not recruiting
• Age: 18 years and older
• Phase 1

This study includes a Dose Escalation Part to identify the recommended combination dose (RCD) and a Dose Expansion Part to further evaluate efficacy and safety.

Trial name

NCT04676477

Testing

HER3-DXd, Osimertinib

Where

31 sites in United States, Japan and 2 more

Volunteers

246 people

Sponsor

Daiichi Sankyo